Am J Transplant, Volume 20, Suppl 3 Archives - Page 167 of 223 - ATC Abstracts

2020 American Transplant Congress
Long-Term Liver Transplant Outcomes: A Single Center Cohort Study
S. A. Mao, K. P. Croome, I. J. Galler, C. B. Taner
Mayo Clinic Florida, Jacksonville, FL
*Purpose: This single center study reviews long-term outcomes of liver transplantation identifying morbidity differences between post-transplant liver patients surviving greater than five years versus those…
2020 American Transplant Congress
Anonymous Living Donor Liver Donation: Establishing A Protocol and Understanding Donors Experience
S. Shan¹, J. Durden¹, T. Seay², P. Vargas³, S. Pelletier³, J. Oberholzer³, C. Argo⁴, N. Goldaracena³
¹School of Medicine, University of Virginia Health System, Charlottesville, VA, ²Division of Transplantation, University of Virginia Health System, Charlottesville, VA, ³Department of Surgery, Division of Transplantation, University of Virginia Health System, Charlottesville, VA, ⁴Department of Medicine-Gastroenterology, University of Virginia Health System, Charlottesville, VA
*Purpose: Anonymous living liver donation (ALLDs) are not as widely accepted as directed donations from friends and family, despite having significant potential to help mitigate…
2020 American Transplant Congress
Acute Portal Vein Thrombosis after Pediatric Living Donor Liver Transplantation: Re-Do Portal Vein Anastomosis vs Thrombectomy and Prophylactic Portal Vein Stenting Through Re-Opened Umbilical Vein- Breaching the Technical Barrier!
A. Thorat, D. Mirza, V. Raut, K. Shah, A. Raj
Organ Transplantation Center, Apollo Hospital New Mumbai, Mumbai, India
*Purpose: Acute portal venous thrombosis (PVT) in perioperative period after living donor liver transplantation (LDLT) in pediatric patients is a serious complication. It can lead…
2020 American Transplant Congress
Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients
L. Al Bizri¹, Z. S. Chaudhry², A. Vahia², J. Williams², J. C. Lemos-Ramirez³, B. Summers⁴, A. Patel⁵, S. Nagai⁶, O. Abreu Lanfranco², M. Ramesh², R. Del Busto², G. Alangaden²
¹Internal Medicine, Henry Ford Health System, Detroit, MI, ²Infectious Disease, Henry Ford Health System, Detroit, MI, ³Department of Transplant Infectious Disease, Memorial Regional Hospital, Hollywood, FL, ⁴Central Pharmacy, Henry Ford Health System, Detroit, MI, ⁵Nephrology, Henry Ford Health System, Detroit, MI, ⁶Surgery Transplant, Henry Ford Health System, Detroit, MI
*Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…
2020 American Transplant Congress
De Novo Malignancy after Liver Transplantation for Alcoholic Cirrhosis: Incidence and Outcomes
M. M. Pascale, E. Nure, G. Bianco, F. Frongillo, S. Agnes
Transplant Unit, Fondazione "Policlinico A. Gemelli" UCSC - Rome, Roma, Italy
*Purpose: De novo malignancy, frequent liver transplant (LT) complication, is one of the long-term major causes of mortality. Risk factors are related to immunosuppressive status,…
2020 American Transplant Congress
Lifetime Survival Estimates Following Solid Organ Transplantation in the United States
C. Graham¹, M. Skeans², Y. Ahn², C. Watson³, A. Barlev⁴
¹RTI Health Solutions, Research Triangle Park, NC, ²Chronic Disease Research Group, Minneapolis, MN, ³Atara Biotherapeutics, South San Francisco, CA, ⁴Atara Biotherapeutics, Thousand Oaks, CA
*Purpose: The Scientific Registry of Transplant Recipients (SRTR) contains detailed patient and graft survival data for all solid organ transplants (SOT) in the United States…
2020 American Transplant Congress
Assessment of Sarcopenia and Obesity by Bioelectrical Impedance Analysis in Transplant and Hepatobiliary Populations
J. Konel¹, T. Kitajima², L. Arevalo¹, N. Murray¹, T. Pietrowsky², D. Venkat², H. Gonzalez², M. Samaniego², M. Abouljoud², S. Nagai²
¹Wayne State University School of Medicine, Detroit, MI, ²Henry Ford Transplant Institute, Detroit, MI
*Purpose: Sarcopenia and obesity are common among transplant and hepatobiliary patients; however, current methods of measuring these risk factors may provide an inadequate representation of…
2020 American Transplant Congress
Implications for Facilitated Pancreas Transplant Allocation with the Removal of Donor Service Area
R. Forbes¹, R. Urban², A. Fox², J. Odorico³, S. Niederhaus⁴
¹Vanderbilt University Medical Center, Nashville, TN, ²United Network for Organ Sharing, Richmond, VA, ³University of Wisconsin, Madison, WI, ⁴University of Maryland, Baltimore, MD
*Purpose: Facilitated Pancreas (FP) Allocation, modified in August 2016 to be metric-based rather than opt-in, defines an eligible center as one that has transplanted at…
2020 American Transplant Congress
Is 3-4+ Liver Fibrosis a Contraindication to Heart Transplantation?
M. Kittleson, J. Patel, D. Chang, E. Kransdorf, D. Geft, K. Nishihara, A. Shen, B. May, L. Czer, F. Esmailian, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Chronic liver disease in patients awaiting heart transplant is seen in patients with biventricular heart failure. This is mostly due to congestive hepatopathy due…
2020 American Transplant Congress
Prevalence of Depression and Antidepressant Use in Cardiac Transplant Candidates and Recipients
D. Wood¹, N. R. Konopasek², J. Powers², G. Kim², M. Marcangelo³, L. Lourenco¹
¹Pharmacy, University of Chicago Medicine, Chicago, IL, ²Cardiology, University of Chicago Medicine, Chicago, IL, ³Psychiatry, University of Chicago Medicine, Chicago, IL
*Purpose: A diagnosis of depression can have negative impacts such as graft loss, suicidal ideation, and mortality in patients pre- and post-heart transplantation (HT). This…